Tigen

Pushing for innovation, relentlessly, that's what drives us at Tigen. Collecting and integrating feedback from the broader ecosystem is part of our learning and growth journey. That's why we participate in incubation events and competitions like the Swiss Innovation Challenge, a three-stage pitching contest, where we are thrilled to have made it to the final round. A huge thank you to the jury for your valuable feedback on the innovation of the product and value proposition, the business plan and the implementation strategy. Thanks also for the hosts and sponsors Rolf-Dieter Reineke, Stefan Philippi, Mathias Welti, Pascal Brenneisen, Beat Röthlisberger, Christoph Buser, Prof. Dr. Arie Hans Verkuil, as well as the Wirtschaftskammer Baselland, Fachhochschule Nordwestschweiz FHNW, and BLKB. It was intense but a lot of fun, see you at the winner's ceremony! #celltherapy #fightcancer #smartcells #innovation #award

#Podcast 🎧: Lymphödem nach Brustkrebs – neue Behandlungsmöglichkeiten Bei der Behandlung von Brustkrebs werden häufig auch Lymphknoten entfernt oder bestrahlt. Bis zu einem Viertel der Frauen entwickelt danach ein sogenanntes #Lymphödem. Dabei staut sich Lymphflüssigkeit im Gewebe es schwillt an und schmerzt stark. Prof. Elisabeth A Kappos, rekonstruktive Chirurgin am Universitätsspital Basel (USB) will diesen Frauen helfen. Betroffene leiden manchmal noch Jahre nach der überstandenen Brustkrebserkrankung unter einem Schweregefühl, Bewegungseinschränkungen und stark eingeschränkter Lebensqualität. Auch Heidi O. hat den Brustkrebs überlebt. Doch nach der Operation schwollen ihre beiden Arme stark an. Dank eines mikrochirurgischen Eingriffs wurde nun – wie bei einem Stau auf der Autobahn – eine Umleitung geschaffen, damit die Lymphflüssigkeit wieder abfliessen kann. Wie es ihr heute geht, erzählt sie in dieser Podcast-Folge. Jetzt Podcast anhören und mehr erfahren: https://lnkd.in/d3ZNPz5r #Krebsforschung #damitHeilungzurRegelwird

Great to be part of a dynamic biotech cluster here in Lausanne and to contribute both from a scientific and entrepreneurial perspective. Tigen's Sérgio Ribeiro sharing his experience at the HUB Entrepreneuriat et Innovation UNIL University of Lausanne - UNIL FBM UNIL - Faculté de biologie et de médecine de l'Université de Lausanne in collaboration with #skillsforscientists #innovation #collaboration #celltherapy #smartcells #impact

Access to breakthrough therapies, that's what's driving the Tigen team every day. Today, we're at Phacilitate Advanced Therapies Europe #ATE24, and our Diego Möckli is sharing insights on how decentralizing and localizing development and manufacturing skills and capacity will create new opportunities for all the stakeholders in the cell and gene therapy ecosystem. #celltherapies #fightcancer #smartcells #innovation #collaboration #digitalisation #nosilos

Good to see you on stage again Therese, exploring on Tigen's efforts around analytics, automation and digitalisation to help accelerate patient access to cell & gene therapies. Enjoy and bring back tons of feedback! #innovation #smartcells #cgt #fightcancer

𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐫𝐞𝐚𝐜𝐡𝐞𝐬 𝐢𝐭𝐬 𝐭𝐮𝐫𝐧𝐢𝐧𝐠 𝐩𝐨𝐢𝐧𝐭: 2 solid tumour breakthroughs in 8 months 👇 On Friday, we celebrated a BIG milestone for cell therapies with the approval of Adaptimmune’s Tecelra + Iovance’s Amtagvi TIL therapy earlier this year. ➡️ These 2 approvals mark a significant leap for treating solid tumours, validating THE PROGRESS of cell therapies and opening new regulatory pathways and refining future research innovations. It could also truly pave the way for cell therapies to extend beyond the six approved liquid tumours/blood cancers. The bottom line is that patients with MSS and advanced melanoma now have an NEW treatment option that offers the vital care they truly deserve 👏 Looking ahead, these breakthroughs create exciting opportunities for further exploration and research collaborations, which could lead to significant advancements in treatment strategies and enhance patient outcomes. 𝘏𝘰𝘸𝘦𝘷𝘦𝘳, 𝘦𝘹𝘦𝘤𝘶𝘵𝘪𝘯𝘨 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭𝘪𝘴𝘢𝘵𝘪𝘰𝘯 𝘪𝘴 𝘷𝘪𝘵𝘢𝘭 and addressing challenges related to the cost and accessibility of these therapies will be crucial in ensuring that their benefits reach a broader patient population to recruit. 𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐲𝐨𝐮𝐫 𝐭𝐡𝐨𝐮𝐠𝐡𝐭𝐬 𝐨𝐧 𝐡𝐨𝐰 𝐭𝐡𝐞 𝐫𝐞𝐜𝐞𝐧𝐭 𝐛𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬 𝐢𝐧 𝐬𝐨𝐥𝐢𝐝 𝐭𝐮𝐦𝐨𝐫 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐦𝐢𝐠𝐡𝐭 𝐢𝐧𝐟𝐥𝐮𝐞𝐧𝐜𝐞 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭? #celltherapy #oncology #biotech #CGTweekly

The 2024 Advanced Therapy Medicinal Products PDA - Parenteral Drug Association conference brought together key voices from the cell therapy ecosystem. Tigen's Ursula Busse shared our view of the roadmap to faster and broader access to breakthrough autologous T cell therapies like CAR T and TILs. Digitalization, automatization, data integration and decentralization are major drivers for the required transformation. The regulators seem all-in while the industry still debates, based on legacy vs progressive arguments. And again, no one can do it alone - we need to consequently work in cross-functional and cross-organizational setups for progress. Thanks for having us and the great colleagues Marsha Steed Richard Denk Jimi Olaghere #biotech #innovation #regulation #celltherapy #cgt #collaboration #fightcancer

Immunotherapies are an important scientific breakthrough. The work of John Haanen, George Coukos and their colleagues at the CHUV | Lausanne university hospital and around the globe, e.g. with TILs or CAR Ts, is so important in making these therapies widely available to patients. Thanks Julien Crevoisier from Invivo magazine for the article. The successful treatment of patients is what drives us every day: https://lnkd.in/emJkuNXV #innovation #research #celltherapy #collaboration #fightcancer

Digital Health does not happen by chance. In the Swiss environment with a high quality perception of the healthcare system and many regional and cantonal initiatives and budgets, it is even more important that scientific breakthrough projects lead the way and hyper-collaboration is fostered wherever possible. Thanks digitalswitzerland and Biopôle Lausanne for involving us and ELCA Group for the close and effective partnership we built. Our Antoine MAISON and Elca's Sébastien Fabbri are always energized to discuss and support digital innovation ventures. -> Have a look at the publication to Kickstart your digital health venture. #digitalhealth #innovation #collaboration #precisionmedicine #celltherapy #fightcancer

High precision is at the core of Tigen's ambition and values. Thanks ELCA Group for the opportunity for Antoine MAISON to share our joint journey with ELCA in the precision medicine field at the EPHJ - The World of High Precision. Precision technology and data literacy go hand in hand with the clinical and medical perspective in advanced therapy medicinal products (ATMPs). In the autologous cell therapy field, we're constantly reminded that only the high collaboration approach will allow for breakthrough innovation. A big thank you also to Daniel Daguerre and Laetitia Mage for sharing the stage. #innovation #collaboration #precision #switzerland #medtech #microtechnology #artificialintelligence #celltherapy #fightcancer